SCHEMBL7708252

SCHEMBL7708252

CC1Oc2ccc(C(Cc3cccc(Cl)c3)NC(=O)OC(C)(C)C)cc2NC1=S

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 1/20 0.45
ALDH1A1 P00352 6/20 0.37
HSD17B10 Q99714 3/20 0.36
CYP3A4 P08684 1/20 0.35
SCN9A Q15858 1/20 0.35
HPGD P15428 4/20 0.35
HTT P42858 4/20 0.35
NPSR1 Q6W5P4 4/20 0.35
KDM4E B2RXH2 3/20 0.35
LMNA P02545 2/20 0.35
PKM P14618 2/20 0.35
KMT2A Q03164 2/20 0.35
JAK2 O60674 2/20 0.35
RCE1 Q9Y256 1/20 0.35
SIRT2 Q8IXJ6 1/20 0.35
SIRT1 Q96EB6 1/20 0.35
XBP1 P17861 2/20 0.35
MEN1 O00255 1/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7711137 0.91 CTSL (0.45) CTSLALDH1A1HSD17B10CYP3A4SCN9A
SCHEMBL7092472 0.91 HSD17B10 (0.37) CTSLALDH1A1HSD17B10HPGDHTT
SCHEMBL7704943 0.91 ALDH1A1 (0.43) CTSLALDH1A1HSD17B10HPGDHTT
SCHEMBL7090483 0.90 CTSS (0.45) CTSLALDH1A1HSD17B10SCN9AHPGD
SCHEMBL7711070 0.90 CACNA1B (0.40) ALDH1A1HSD17B10HPGDHTTNPSR1
SCHEMBL7091267 0.89 HSD17B10 (0.33) CTSLALDH1A1HSD17B10HPGDHTT
SCHEMBL7091516 0.89 SCN9A (0.39) ALDH1A1HSD17B10SCN9AHPGDHTT
SCHEMBL7708478 0.88 HSD17B10 (0.35) CTSLALDH1A1HSD17B10HPGDHTT
SCHEMBL7095517 0.87 SIRT2 (0.38) ALDH1A1HSD17B10HPGDHTTNPSR1
SCHEMBL7093383 0.87 MC4R (0.41) CTSLALDH1A1HSD17B10CYP3A4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed